Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States
Carla J. Berg, Darcey M. Mccready, Cassidy R. Loparco, Laura C. Schubel, Katelyn F. Romm, Shriya Thakkar, Jessica Williams, Patricia Cavazos‐rehg, Y. Tony Yang
Journal of Psychoactive Drugs June 19, 2026 Peer reviewed DOI: 10.1080/02791072.2026.2685527 via OpenAlex
Summary
In a sample of young adults, 27.7% reported lifetime psychedelic use, with 11.9% using in the past year, primarily psilocybin/amanita, MDMA, and LSD. Notably, 48.8% used psychedelics solely for nonmedical reasons. Among lifetime users, 26.5% had microdosed. Factors influencing use included sociodemographics and mental health symptoms, such as depressive and anxiety symptoms, along with adverse childhood events (ACEs). The findings highlight the need to understand mental health impacts on substance use behaviors.
Study at a glance
| Design | observational cohort |
|---|---|
| Sample size | 26 |
| Population | young adults who completed an online survey |
| Key finding | Mental health symptoms and adverse childhood events were associated with psychedelic use, microdosing, and higher use motives. |
Abstract
= 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use were 27.7% and 11.9% (commonly psilocybin/amanita, MDMA, and LSD); 48.8% used only for nonmedical purposes. Of those reporting lifetime use, 26.5% ever microdosed. Correlates of use-related outcomes varied: (1) lifetime use: older, male (vs female), Black (vs White), metropolitan/urban (vs rural), more depressive symptoms and ACEs; (2) microdosing: not having children, more anxiety symptoms and ACEs; (3) higher expansion motives: male, White (vs Asian), more anxiety symptoms and ACEs; (4) higher mood/social enhancement motives: more depressive symptoms; and (5) higher symptom management motives: male, Hispanic, more depressive symptoms and ACEs. Despite half using exclusively for nonmedical purposes, mental health symptoms and ACEs were associated with use, microdosing, and higher use motives. Understanding the role of mental health across sociodemographic groups is necessary to address possible adverse outcomes.